Isolated limb perfusion based anti-p21ras gene therapy in a rat rhabdomyosarcoma

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2295-2301

  Van Etten, Boudewijn ^a   Van Tiel, Sandra T ^a   Ambagtsheer, Gisela ^a   Eggermont, Alexander M M ^a   Ten Hagen, Timo L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adenovirus; Gene therapy; Isolated perfusion; Ras oncogene; Rhabdomyosarcoma

Indexed keywords

ADENOVIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE THERAPY; GENE TRANSFER; LIMB PERFUSION; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; RAT; RHABDOMYOSARCOMA; TREATMENT OUTCOME; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; GENE THERAPY; GENES, RAS; GENETIC VECTORS; IMMUNOGLOBULIN FRAGMENTS; PROTO-ONCOGENE PROTEINS P21(RAS); RATS; RHABDOMYOSARCOMA; TRANSFECTION;

EID: 4444369934     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bos JL: Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-9, 1989.
2. Chang MY, Won SJ and Liu HS: A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines. J Cancer Res Clin Oncol 123: 91-9, 1997.
3. Cochet O, Kenigsberg M, Delumeau I, Duchesne M, Schweighoffer F, Tocque B et al: Intracellular expression and functional properties of an anti-p21Ras scfv derived from a rat hybridoma containing specific lambda and irrelevant kappa light chains. Mol Immunol 35: 1097-110, 1998.
4. Cochet O, Kenigsberg M, Delumeau I, Virone-Oddos A, Multon MC, Fridman WH et al: Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res 58: 1170-6, 1998.
5. Eastham JA and Ahlering TE: Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line. J Urol 156: 1186-8, 1996.
6. Feng M, Cabrera G, Deshane J, Scanlon KJ and Curiel DT: Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 55: 2024-8, 1995.
7. Fenton RG, Keller CJ, Hanna N and Taub DD: Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli. J Natl Cancer Inst 87: 1853-61, 1995.
8. Geiser AG, Anderson MJ and Stanbridge EJ: Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated ras oncogenes. Cancer Res 49: 1572-7, 1989.
9. Georges RN, Mukhopadhyay T, Zhang Y, Yen N and Roth JA: Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res 53: 1743-6, 1993.
10. Gray GD, Hernandez OM, Hebel D, Root M, Pow-Sang JM and Wickstrom E: Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. Cancer Res 53: 577-80, 1993.
11. Kashani-Sabet M, Funato T, Florenes VA, Fodstad O and Scanlon KJ: Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res 54: 900-2, 1994.
12. Li M, Lonial H, Citarella R, Lindh D, Colina L and Kramer R: Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer. Cancer Gene Ther 3: 221-9, 1996.
13. van Etten B, ten Hagen TL, de Vries MR, Ambagtsheer G, Huet T and Eggermont AM: Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras. Br J Cancer 86: 436-42, 2002.
14. Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D et al: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224: 756-64, discussion 764-5, 1996.
15. Eggermont AM, Schraffordt Koops H, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ et al: Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14: 2653-65, 1996.
16. Fraker DL, Alexander HR, Andrich M and Rosenberg SA: Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 14: 479-89, 1996.
17. Lienard D, Ewalenko P, Delmotte JJ, Renard N and Lejeune FJ: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52-60, 1992.
18. Manusama ER, Stavast J, Durante NM, Marquet RL and Eggermont AM: Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol 22: 152-7, 1996.
19. Manusama ER, Nooijen PT, Stavast J, Durante NM, Marquet RL and Eggermont AM: Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg 83: 551-5, 1996.
20. de Wilt JH, Manusama ER, van Tiel ST, van IJken MG, ten Hagen TL and Eggermont AM: Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 80: 161-6, 1999.
21. Eggermont AM: TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives. Anticancer Res 18: 3899-905, 1998.
22. de Roos WK, de Wilt JH, van Der Kaaden ME, Manusama ER, de Vries MW, Bout A et al: Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas. Ann Surg 232: 814-21, 2000.
23. Milas M, Feig B, Yu D, Oriuchi N, Cromeens D, Ge T et al: Isolated limb perfusion in the sarcoma-bearing rat: a novel preclinical gene delivery system. Clin Cancer Res 3: 2197-203, 1997.
24. Werge TM, Biocca S and Cattaneo A: Intracellular immunization. Cloning and intracellular expression of a monoclonal antibody to the p21ras protein. FEBS Lett 274: 193-8, 1990.
25. Furth ME, Davis LJ, Fleurdelys B and Scolnick EM: Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family. J Virol 43: 294-304, 1982.
26. Hermens AF and Bentvelzen PA: Influence of the H-ras oncogene on radiation responses of a rat rhabdomyosarcoma cell line. Cancer Res 52: 3073-82,1992.
27. Nooter K, Boersma AW, Oostrum RG, Burger H, Jochemsen AG and Stoter G: Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line. Br J Cancer 71: 556-61, 1995.
28. Reddy EP, Reynolds RK, Santos E and Barbacid M: A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300: 149-52, 1982.
29. Davies I and Gimenez A: A new selective agent for eukaryotic cloning vectors. Am J Trop Med Hyg 20: 1089-92, 1980.
30. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D et al: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-12, 1990.
31. Russell JS, Lang FF, Huet T, Janicot M, Chada S, Wilson DR, et al: Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment. Cancer Res 59: 5239-44, 1999.
32. de Wilt JH, Bout A, Eggermont AM, van Tiel ST, de Vries MW, ten Hagen TL et al: Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats. Hum Gene Ther 12: 489-502, 2001.
33. Ghazal P, Lubon H, Fleckenstein B and Hennighausen L: Binding of transcription factors and creation of a large nucleoprotein complex on the human cytomegalovirus enhancer. Proc Natl Acad Sci USA 84: 3658-62, 1987.
34. van Etten B, de Vries MR, van IJken MG, Lans TE, Guetens G, Ambagtsheer G et al: Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer 88: 314-9, 2003.
35. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-3, 1997.
36. Huard J, Lochmuller H, Acsadi G, Jani A, Massie B and Karpati G: The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 2: 107-15, 1995.